Hologic (HOLX) has disclosed a new risk, in the Sales & Marketing category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hologic faces significant business risks due to third-party reimbursement and guideline challenges. The company’s reliance on government healthcare programs and private insurers for coverage decisions and reimbursement policies means that any adverse changes could impact sales and market acceptance of their diagnostics, breast and skeletal health, and surgical products. Variations in reimbursement policies across different countries further complicate the acceptance of new products. Additionally, guidelines and recommendations from professional societies and organizations, such as those from the American Cancer Society and the U.S. Preventive Services Task Force, have already influenced the use of Hologic’s products, potentially reducing demand and affecting revenue streams.
The average HOLX stock price target is $79.22, implying 6.81% upside potential.
To learn more about Hologic’s risk factors, click here.